Evaluating the efficacy of neoadjuvant endocrine therapy in HER2 low vs. HER2 negative breast cancer: An NCBD analysis

被引：0
|
作者：
Chong, Esther G.
Guo, Mengni
Castillo, Dani Ran
Bazan, Jose G.
Yap, Kelly Khai Li
Schultz-Costello, Katharine
Wu, S. Peter
机构：
[1] Loma Linda Univ, Dept Oncol Hematol, Med Ctr, Loma Linda, CA USA
[2] City Hope Natl Canc Ctr, Duarte, CA USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
599
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Survival analysis of HER2 receptor negative and HER2 receptor low breast cancer patients at a Philippine hospital
    Arenos, C. C.
    San Juan, M.
    Lim, S.
    Lominoque, A.
    Reveldez, I.
    Sison-DImaano, A.
    Pangandaman, N.
    Tatoy, V.
    Uy, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1390 - S1390
  • [12] HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer
    Mazumder, Aloran
    Shiao, Stephen
    Haricharan, Svasti
    ENDOCRINOLOGY, 2021, 162 (10)
  • [13] Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
    Bose, Ron
    Kavuri, Shyam M.
    Searleman, Adam C.
    Shen, Wei
    Shen, Dong
    Koboldt, Daniel C.
    Monsey, John
    Goel, Nicholas
    Aronson, Adam B.
    Li, Shunqiang
    Ma, Cynthia X.
    Ding, Li
    Mardis, Elaine R.
    Ellis, Matthew J.
    CANCER DISCOVERY, 2013, 3 (02) : 224 - 237
  • [14] Neoadjuvant therapy in patients with triple negative and HER2 positive early breast cancer
    Harbeck, N.
    BREAST, 2017, 32 : S18 - S18
  • [15] Impact of neoadjuvant HER2-directed therapy on HER2 status in breast cancer
    Manguso, Nicholas
    Johnson, Jeffrey
    Basho, Reva Kakkar
    McArthur, Heather L.
    Tanaka, Hisashi
    Giuliano, Armando E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [16] Prognostic factors in nonmetastatic HER2 'low' & HER2 'negative' breast cancer: Single institute experience
    Turkel, A.
    Dogan, M.
    Sertesen, E.
    Karacin, C.
    Irkkan, S. C.
    Ates, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S299 - S300
  • [17] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Chen, Zhaoxu
    Jia, Huiqing
    Zhang, Huina
    Chen, Lifang
    Zhao, Peng
    Zhao, Jing
    Fu, Guangming
    Xing, Xiaoming
    Li, Yujun
    Wang, Chengqin
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (02) : 313 - 323
  • [18] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Zhaoxu Chen
    Huiqing Jia
    Huina Zhang
    Lifang Chen
    Peng Zhao
    Jing Zhao
    Guangming Fu
    Xiaoming Xing
    Yujun Li
    Chengqin Wang
    Breast Cancer Research and Treatment, 2023, 202 : 313 - 323
  • [19] HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?
    Landmann, Alessandra
    Farrugia, Daniel J.
    Diego, Emilia
    Bonaventura, Marguerite
    Soran, Atilla
    Johnson, Ronald
    Dabbs, David J.
    Clark, Beth
    Brufsky, Adam
    Davidson, Nancy E.
    Lembersky, Barry C.
    Jankowitz, Rachel Catherine
    Puhalla, Shannon
    Ahrendt, Gretchen M.
    McAuliffe, Priscilla F.
    Bhargava, Rohit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [20] Sparing chemotherapy with dual HER2 blockade in combination with endocrine therapy for advanced HER2 positive breast cancer
    Werutsky, Gustavo
    Reinert, Tomas
    Fay, Andre Poisl
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S573 - S576
12345